Arrowhead Research | ARWR - Assets

Stock Price
63.59
Daily Change
-0.27 -0.42%
Monthly
-5.93%
Yearly
219.55%
Q1 Forecast
61.62

Arrowhead Research reported $1.6B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Anika Therapeutics USD 189.44M 1.76M Sep/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
Heron Therapeutics USD 248.95M 16.86M Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Ligand Pharmaceuticals USD 1.48B 528.17M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
TG Therapeutics USD 1.03B 322.41M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xencor USD 868.81M 10.61M Sep/2025